K
Kalitherapeutics
Kali Therapeutics develops next-generation trispecific T-cell engagers designed to induce a precise immune system reset for treating autoimmune diseases. Their platform utilizes controlled cytotoxicity to target and eliminate pathogenic immune cells. This approach aims to restore immune balance and promote long-term health outcomes for patients.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Kali Therapeutics develops novel trispecific T-cell engagers (TCEs) designed for precise targeting and controlled cytotoxicity. This platform aims to achieve a transformative immune system reset for patients suffering from autoimmune diseases. The company focuses on engineering these biologics to restore immune balance and promote long-term health outcomes.